Tarsus Pharmaceuticals Statistics
Total Valuation
TARS has a market cap or net worth of $1.04 billion. The enterprise value is $772.29 million.
| Market Cap | 1.04B |
| Enterprise Value | 772.29M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TARS has 37.78 million shares outstanding. The number of shares has increased by 32.00% in one year.
| Shares Outstanding | 37.78M |
| Shares Change (YoY) | +32.00% |
| Shares Change (QoQ) | +5.89% |
| Owned by Insiders (%) | 8.66% |
| Owned by Institutions (%) | 109.78% |
| Float | 23.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.46 |
| Forward PS | 6.11 |
| PB Ratio | 3.78 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.01, with a Debt / Equity ratio of 0.11.
| Current Ratio | 8.01 |
| Quick Ratio | 7.76 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.66 |
Financial Efficiency
Return on equity (ROE) is -71.10% and return on invested capital (ROIC) is -51.09%.
| Return on Equity (ROE) | -71.10% |
| Return on Assets (ROA) | -55.30% |
| Return on Capital (ROIC) | -51.09% |
| Revenue Per Employee | $174,430 |
| Profits Per Employee | -$607,398 |
| Employee Count | 244 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +59.25% in the last 52 weeks. The beta is 1.10, so TARS's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +59.25% |
| 50-Day Moving Average | 32.92 |
| 200-Day Moving Average | 26.01 |
| Relative Strength Index (RSI) | 39.15 |
| Average Volume (20 Days) | 815,265 |
Short Selling Information
The latest short interest is 7.96 million, so 21.08% of the outstanding shares have been sold short.
| Short Interest | 7.96M |
| Short Previous Month | 7.48M |
| Short % of Shares Out | 21.08% |
| Short % of Float | 33.28% |
| Short Ratio (days to cover) | 15.53 |
Income Statement
In the last 12 months, TARS had revenue of $42.56 million and -$148.21 million in losses. Loss per share was -$4.73.
| Revenue | 42.56M |
| Gross Profit | 39.31M |
| Operating Income | -155.89M |
| Pretax Income | -148.21M |
| Net Income | -148.21M |
| EBITDA | -143.00M |
| EBIT | -144.56M |
| Loss Per Share | -$4.73 |
Balance Sheet
The company has $298.52 million in cash and $29.93 million in debt, giving a net cash position of $268.59 million or $7.11 per share.
| Cash & Cash Equivalents | 298.52M |
| Total Debt | 29.93M |
| Net Cash | 268.59M |
| Net Cash Per Share | $7.11 |
| Equity (Book Value) | 275.21M |
| Book Value Per Share | 7.28 |
| Working Capital | 298.20M |
Cash Flow
In the last 12 months, operating cash flow was -$133.31 million and capital expenditures -$5.34 million, giving a free cash flow of -$138.65 million.
| Operating Cash Flow | -133.31M |
| Capital Expenditures | -5.34M |
| Free Cash Flow | -138.65M |
| FCF Per Share | -$3.93 |
Margins
Gross margin is 92.37%, with operating and profit margins of -366.27% and -348.22%.
| Gross Margin | 92.37% |
| Operating Margin | -366.27% |
| Pretax Margin | -348.22% |
| Profit Margin | -348.22% |
| EBITDA Margin | -335.98% |
| EBIT Margin | -339.65% |
| FCF Margin | -325.76% |
Dividends & Yields
TARS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.00% |
| Shareholder Yield | -32.00% |
| Earnings Yield | -14.24% |
| FCF Yield | -13.32% |
Analyst Forecast
The average price target for TARS is $50.83, which is 84.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.83 |
| Price Target Difference | 84.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 112.46% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TARS has an Altman Z-Score of 7.09 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.09 |
| Piotroski F-Score | 2 |